These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24142995)

  • 1. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.
    Dietrich S; Okun JG; Schmidt K; Falk CS; Wagner AH; Karamustafa S; Radujkovic A; Hegenbart U; Ho AD; Dreger P; Luft T
    Haematologica; 2014 Mar; 99(3):541-7. PubMed ID: 24142995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.
    Luft T; Dietrich S; Falk C; Conzelmann M; Hess M; Benner A; Neumann F; Isermann B; Hegenbart U; Ho AD; Dreger P
    Blood; 2011 Aug; 118(6):1685-92. PubMed ID: 21636856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
    Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Rotta M; Storer BE; Storb R; Martin PJ; Flowers ME; Vernon MS; Peffer A; Maloney DG; Deeg HJ; Sandmaier BM; Appelbaum FR; Mielcarek M
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1463-6. PubMed ID: 20685260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation.
    Radujkovic A; Dai H; Kordelas L; Beelen D; Rachakonda SP; Müller-Tidow C; Kumar R; Dreger P; Luft T
    Haematologica; 2019 Apr; 104(4):827-834. PubMed ID: 30514796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
    Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
    Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
    Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
    Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
    Kim SS
    Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.
    Kuçi Z; Bönig H; Kreyenberg H; Bunos M; Jauch A; Janssen JW; Škifić M; Michel K; Eising B; Lucchini G; Bakhtiar S; Greil J; Lang P; Basu O; von Luettichau I; Schulz A; Sykora KW; Jarisch A; Soerensen J; Salzmann-Manrique E; Seifried E; Klingebiel T; Bader P; Kuçi S
    Haematologica; 2016 Aug; 101(8):985-94. PubMed ID: 27175026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.
    Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Borjas-Almaguer OD; González-Llano O; Jaime-Pérez JC; Solano-Genesta M; Gómez-Guijosa M; Mancias-Guerra C; Tarin L; Gómez-Almaguer D
    Haematologica; 2012 May; 97(5):717-22. PubMed ID: 22133770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Hattori K; Doki N; Kurosawa S; Hino Y; Yamamoto K; Sakaguchi M; Harada K; Ikegawa S; Shingai N; Senoo Y; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Ann Hematol; 2017 Feb; 96(2):319-321. PubMed ID: 27766393
    [No Abstract]   [Full Text] [Related]  

  • 18. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
    Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
    Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical
    Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
    Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
    Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
    Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.